Apellis Receives Permanent J-Code for GA Drug Syfovre

The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a permanent and product-specific J-code (J2781) for Apellis Pharmaceuticals' Syfovre (pegcetacoplan injection), the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. The J-code for Syfovre will become effective on October 1, 2023.

J-codes are permanent reimbursement codes used by government payers and commercial insurers to facilitate billing of Medicare Part B treatments, which must be administered by a health care professional. J-codes simplify and streamline the billing and reimbursement processes, allowing for efficient claims processing.

The permanent J-code has been published by CMS here.

"Until Syfovre, patients had nothing to slow the progression of this relentless and irreversible disease,” Adam Townsend, chief commercial officer, Apellis, said in a company news release. “The permanent J-code is a significant milestone that will help ensure accurate and efficient reimbursement of Syfovre in all treatment settings, building on our goal of bringing this important treatment to GA patients in need.”